ACAD
30
-3
-9.09%
AEMD
5.1
-0.06
-1.16%
APRI
0.47
-0.03
-5.11%
ARNA
1.62
-0.09
-5.26%
ATEC
0.23
+0.01
+2.22%
CNAT
2.68
-0.04
-1.47%
CRXM
0.19
0.00
0.00%
CYTX
0.271
-0.029
-9.8033%
DXCM
63.08
-2.02
-3.10%
GNMK
5.7
-0.14
-2.40%
HALO
10.22
-0.63
-5.81%
ILMN
133.65
-2.27
-1.67%
INNV
0.086
0.00
0.00%
INO
10.36
-0.52
-4.78%
ISCO
3.73
+0.01
+0.27%
ISIS
57.56
0.00
0.00%
LGND
119.9
-3.12
-2.54%
LPTN
0.25
+0.03
+16.28%
MBVX
0.66
0.00
0.00%
MEIP
1.42
-0.02
-1.39%
MNOV
6.84
-0.16
-2.29%
MRTX
20.21
-1.34
-6.22%
MSTX
0.319
+0.029
+9.962%
NBIX
45.05
-1.66
-3.55%
NUVA
52.16
-0.45
-0.86%
ONCS
1.82
-0.06
-3.19%
ONVO
2.71
-0.12
-4.24%
OREX
0.462
-0.005
-1.0493%
OTIC
13.84
-0.12
-0.86%
QDEL
16.92
-0.26
-1.51%
RCPT
231.96
0.00
0.00%
RGLS
5.44
-0.49
-8.26%
RMD
55.64
-0.49
-0.87%
SPHS
1.41
+0.07
+5.22%
SRNE
6.83
-0.15
-2.15%
TROV
3.75
-0.24
-6.02%
VICL
0.38
0.00
-0.05%
VOLC
18
0.00
0.00%
ZGNX
10.28
-0.05
-0.48%
ACAD
30
-3
-9.09%
AEMD
5.1
-0.06
-1.16%
APRI
0.47
-0.03
-5.11%
ARNA
1.62
-0.09
-5.26%
ATEC
0.23
+0.01
+2.22%
CNAT
2.68
-0.04
-1.47%
CRXM
0.19
0.00
0.00%
CYTX
0.271
-0.029
-9.8033%
DXCM
63.08
-2.02
-3.10%
GNMK
5.7
-0.14
-2.40%
HALO
10.22
-0.63
-5.81%
ILMN
133.65
-2.27
-1.67%
INNV
0.086
0.00
0.00%
INO
10.36
-0.52
-4.78%
ISCO
3.73
+0.01
+0.27%
ISIS
57.56
0.00
0.00%
LGND
119.9
-3.12
-2.54%
LPTN
0.25
+0.03
+16.28%
MBVX
0.66
0.00
0.00%
MEIP
1.42
-0.02
-1.39%
MNOV
6.84
-0.16
-2.29%
MRTX
20.21
-1.34
-6.22%
MSTX
0.319
+0.029
+9.962%
NBIX
45.05
-1.66
-3.55%
NUVA
52.16
-0.45
-0.86%
ONCS
1.82
-0.06
-3.19%
ONVO
2.71
-0.12
-4.24%
OREX
0.462
-0.005
-1.0493%
OTIC
13.84
-0.12
-0.86%
QDEL
16.92
-0.26
-1.51%
RCPT
231.96
0.00
0.00%
RGLS
5.44
-0.49
-8.26%
RMD
55.64
-0.49
-0.87%
SPHS
1.41
+0.07
+5.22%
SRNE
6.83
-0.15
-2.15%
TROV
3.75
-0.24
-6.02%
VICL
0.38
0.00
-0.05%
VOLC
18
0.00
0.00%
ZGNX
10.28
-0.05
-0.48%
Home » Bio: Keith Murphy

Bio: Keith Murphy

Keith Murphy, chairman and chief executive officer, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has more than 17 years of experience in biotechnology, including serving in product strategy and director of process development roles at Amgen. His 10 years at Amgen included four years as global operations leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a B.S. in chemical engineering from MIT and is an alumnus of the UCLA Anderson School of Management.